Profile data is unavailable for this security.
About the company
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
- Revenue in NOK (TTM)43.97m
- Net income in NOK-43.36m
- Incorporated2011
- Employees22.00
- LocationArctic Bioscience ASIndustrivegen 42ORSTA 6155NorwayNOR
- Websitehttps://arctic-bioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Double Bond Phrmcutcl Intrntnl AB (publ) | 298.56k | -901.75k | 27.08m | 9.00 | -- | 2.11 | -- | 90.71 | -0.02 | -0.02 | 0.0035 | 0.056 | 0.027 | -- | 2.99 | 30,961.11 | -8.16 | -75.46 | -11.26 | -104.36 | 2,263.63 | -717.21 | -302.04 | -1,144.39 | -- | 0.78 | 0.00 | -- | -20.52 | 35.18 | 58.98 | -- | 114.06 | -- |
| ExpreS2ion Biotech Holding AB | 11.63m | -48.40m | 59.84m | 20.00 | -- | 1.26 | -- | 5.15 | -44.22 | -44.22 | 5.14 | 12.52 | 0.1305 | -- | 5.67 | 571,157.90 | -54.33 | -58.63 | -85.25 | -70.70 | 55.64 | -18.17 | -416.26 | -621.40 | -- | -- | 0.0433 | -- | -11.07 | -10.76 | 60.57 | -- | 5.08 | -- |
| Pila Pharma AB | 1.03m | -12.06m | 59.88m | 0.00 | -- | 34.85 | -- | 58.35 | -0.3702 | -0.3702 | 0.0315 | 0.0381 | 0.2406 | -- | 7.20 | -- | -282.78 | -113.42 | -602.96 | -128.21 | -679.51 | -118.10 | -1,175.22 | -1,491.09 | -- | -136.10 | 0.00 | -- | -47.03 | 17.47 | -13.21 | -- | -- | -- |
| XP Chemistries AB | 333.72k | -8.21m | 62.91m | 2.00 | -- | 1.48 | -- | 188.50 | -0.042 | -0.042 | 0.0017 | 0.126 | 0.0095 | 3.58 | 9.76 | 155,735.00 | -23.42 | -- | -25.03 | -- | -1,850.65 | -- | -2,461.64 | -- | 17.17 | -- | 0.00 | -- | -57.22 | -- | 11.26 | -- | -- | -- |
| Odi Pharma AB (publ) | 9.61m | -5.06m | 64.42m | 1.00 | -- | 205.52 | -- | 6.70 | -0.2851 | -0.2851 | 0.5266 | 0.016 | 1.33 | -- | 5.29 | 8,971,460.00 | -70.09 | -40.68 | -1,151.76 | -60.97 | -29.08 | -- | -52.61 | -95.17 | -- | -8.51 | 0.00 | -- | -85.94 | -- | -944.49 | -- | -- | -- |
| Oncozenge AB | 2.91m | -9.17m | 78.32m | 1.00 | -- | 7.86 | -- | 26.94 | -0.7136 | -0.7136 | 0.2282 | 0.7357 | 0.162 | -- | 3.75 | 2,713,000.00 | -51.09 | -- | -58.48 | -- | -- | -- | -315.33 | -- | -- | -610.07 | 0.4463 | -- | -- | -- | 45.37 | -- | -- | -- |
| Arctic Bioscience AS | 43.97m | -43.36m | 93.54m | 22.00 | -- | 0.4772 | -- | 2.13 | -1.67 | -1.67 | 1.69 | 7.27 | 0.156 | 0.9957 | 4.02 | 1,998,510.00 | -15.39 | -15.49 | -18.84 | -17.83 | 28.45 | 28.52 | -98.62 | -125.49 | 0.3389 | -9.68 | 0.2202 | -- | 28.84 | 7.68 | -5.31 | -- | -- | -- |
| StenoCare A/S | 8.60m | -37.26m | 94.75m | 8.00 | -- | 25.19 | -- | 11.02 | -0.8176 | -0.8176 | 0.1569 | 0.0572 | 0.324 | -- | 3.80 | 709,217.50 | -140.37 | -45.69 | -201.07 | -59.64 | -- | -- | -433.19 | -739.04 | 1.32 | -6.51 | 0.526 | -- | -40.60 | -14.70 | -96.30 | -- | -64.95 | -- |
| Enorama Pharma AB | 4.10m | -82.04m | 108.29m | 5.00 | -- | -- | -- | 26.44 | -1.23 | -1.23 | 0.0595 | -0.0623 | 0.1413 | 2.71 | 2.45 | 764,600.00 | -283.01 | -88.96 | -526.84 | -127.92 | -302.88 | 15.72 | -2,002.90 | -488.89 | 0.5223 | -12.77 | -- | -- | 1,061.12 | 15.68 | 1.81 | -- | -- | -- |
| Vivesto AB | 0.00 | -38.27m | 112.99m | 4.00 | -- | 0.3948 | -- | -- | -0.0664 | -0.0664 | 0.00 | 0.2483 | 0.00 | -- | -- | 0.00 | -21.35 | -- | -23.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.12 | -- | -- | -- |
| IRLAB Therapeutics AB | 91.67m | -98.48m | 153.65m | 31.00 | -- | 2.65 | -- | 1.68 | -1.56 | -1.56 | 1.40 | 0.6382 | 0.5172 | -- | 8.93 | 3,168,815.00 | -55.56 | -27.34 | -149.51 | -32.01 | -35.80 | -45.70 | -107.43 | -112.19 | -- | -4.29 | 0.3548 | -- | 1,566.57 | 415.48 | 53.26 | -- | 7.75 | -- |
| Isofol Medical AB (publ) | 0.00 | -58.38m | 180.56m | 6.00 | -- | 1.40 | -- | -- | -0.2698 | -0.2698 | 0.00 | 0.4291 | 0.00 | -- | -- | 0.00 | -43.21 | -61.58 | -51.19 | -82.71 | -- | -740.36 | -- | -861.94 | -- | -- | 0.00 | -- | -100.00 | -- | -17.31 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Arctic Bioscience AS's reporting currency: Norwegian Krone NOK
0.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cicero Fonder ABas of 31 Mar 2023 | 46.52k | 0.17% |
| Fj�rde AP-fondenas of 30 Jun 2025 | 0.00 | 0.00% |
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
